𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of protein deficient diets on the developmental toxicity of inorganic arsenic in mice

✍ Scribed by Carol A. Lammon; Ronald D. Hood


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
128 KB
Volume
71
Category
Article
ISSN
1542-9733

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND: Inorganic arsenic, when given by injection to pregnant laboratory animals (mice, rats, hamsters), has been shown to induce malformations. Arsenic methylation may be a detoxification step, and diets deficient in protein are a poor source of methyl donors and may possibly result in impaired arsenic methylation. Human health effects from chronic arsenic exposure have been reported mainly in populations with low socioeconomic status. Individuals in such populations are likely to suffer from malnutrition, which can compromise embryonic/fetal development and diminish arsenic methylating capacity. We sought to determine if dietary protein deficiency affects the developmental toxicity of inorganic arsenic. METHODS: Mated females were randomly assigned to one of 12 treatment groups. Experimental groups received either AsIII or AsV i.p. on Gestation Day 8 (GD 8, plug=GD 0) and were maintained on a 5%, 10%, or 20% protein custom mixed diet from GD 1 until sacrifice. Controls received the custom diets alone, were given AsIII or AsV i.p. on GD 8 with Teklad LM‐485 rodent diet, or were fed the LM‐485 diet alone. Test females were sacrificed on GD 17, and their litters were examined for mortality and developmental defects. RESULTS: Arsenic plus dietary protein deficiency decreased maternal weight gain and increased the incidences of exencephaly, ablepharia, and skeletal defects, such as malformed vertebral centra, fused ribs, and abnormal sternebrae (bipartite, rudimentary, or unossified). CONCLUSIONS: These results demonstrate that dietary protein deficiency enhances the developmental toxicity of inorganic arsenic, possibly by impairment of arsenic methylation. Birth Defects Res B 71:124–134, 2004. Β© 2004 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Pretreatment with periodate-oxidized ade
✍ Carol A. Lammon; X. Chris Le; Ronald D. Hood πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 128 KB πŸ‘ 1 views

## Abstract **BACKGROUND:** Inorganic arsenic, given by injection to pregnant laboratory animals, can induce malformations. Arsenic methylation can be inhibited by periodate‐oxidized adenosine (PAD). Severe human health effects from high chronic arsenic exposure have mainly been reported in populat

Developmental toxicity of cysteamine in
✍ Beckman, D. A.; Mullin, J. J.; Assadi, F. K. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 58 KB πŸ‘ 2 views

The reproductive and developmental safety of cysteamine has become an important issue to children with cystinosis because renal transplants and treatment with cysteamine reduce the complications associated with cystinosis and increase the lifespan of the affected children. In addition, there is the

Protective effect of liposome encapsulat
✍ Scialli, Anthony R.; Waterhouse, Timothy B.; Desesso, John M.; Rahman, Aquilur; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 51 KB πŸ‘ 2 views

Paclitaxel is an anticancer drug that has demonstrated severe embryotoxicity in chicks. This embryotoxicity is reduced by liposome encapsulation of the drug. The current study was designed to evaluate the potential of liposome encapsulation for reducing paclitaxel embryotoxicity in rats. Wistar rats